Baseline modified Glasgow prognostic score associated with survival in metastatic urothelial cell carcinoma treated with immune checkpoint inhibitors
Oncologist. 2021 Feb 25. doi: 10.1002/onco.13727. Online ahead of print.ABSTRACTBACKGROUND: The modified Glasgow Prognostic Score (mGPS), a clinical tool that incorporates albumin and C-reactive protein, has proven useful in the prognostication of multiple cancers. Several immune checkpoint inhibitors (ICI) have been approved for the treatment of metastatic urothelial cell carcinoma (mUC) but a prognostic biomarker is needed. We investigated the impact of mGPS on survival outcomes in mUC patients receiving ICI.METHODS: We retrospectively reviewed mUC patients treated with ICI (PD-1 or PD-L1 inhibitors) at Winship Cancer In...
Source: The Oncologist - February 26, 2021 Category: Cancer & Oncology Authors: Jacqueline T Brown Yuan Liu Julie M Shabto Dylan J Martini Deepak Ravindranathan Emilie Elise Hitron Greta Anne Russler Sarah Caulfield Lauren Beth Yantorni Shreyas S Joshi Haydn Kissick Kenneth Ogan Wayne B Harris Bradley C Carthon Omer Kucuk Viraj A Mas Source Type: research

Baseline modified Glasgow prognostic score associated with survival in metastatic urothelial cell carcinoma treated with immune checkpoint inhibitors
Oncologist. 2021 Feb 25. doi: 10.1002/onco.13727. Online ahead of print.ABSTRACTBACKGROUND: The modified Glasgow Prognostic Score (mGPS), a clinical tool that incorporates albumin and C-reactive protein, has proven useful in the prognostication of multiple cancers. Several immune checkpoint inhibitors (ICI) have been approved for the treatment of metastatic urothelial cell carcinoma (mUC) but a prognostic biomarker is needed. We investigated the impact of mGPS on survival outcomes in mUC patients receiving ICI.METHODS: We retrospectively reviewed mUC patients treated with ICI (PD-1 or PD-L1 inhibitors) at Winship Cancer In...
Source: The Oncologist - February 26, 2021 Category: Cancer & Oncology Authors: Jacqueline T Brown Yuan Liu Julie M Shabto Dylan J Martini Deepak Ravindranathan Emilie Elise Hitron Greta Anne Russler Sarah Caulfield Lauren Beth Yantorni Shreyas S Joshi Haydn Kissick Kenneth Ogan Wayne B Harris Bradley C Carthon Omer Kucuk Viraj A Mas Source Type: research

Mismatch Repair (MMR) gene alteration and BRAF V600E mutation are potential predictive biomarkers of immune checkpoint inhibitors in MMR-deficient colorectal cancer
In this study, we evaluated molecular and clinical predictors of ICI response in MMR-D CRC.PATIENTS AND METHODS: Patient databases at 4 cancer institutions were queried. The Fisher exact test was performed to test the association of clinical and molecular markers. The Kaplan-Meier method was used to estimate progression free survival (PFS) and compared by the log-rank test. Twelve- and 24-month PFS rates were compared by the Z test.RESULTS: A total of 60 CRC patients with MMR-D/MSI-H who previously received ICI were identified. Patients with liver metastasis had a lower overall response rate (ORR) as compared to other site...
Source: The Oncologist - February 25, 2021 Category: Cancer & Oncology Authors: Ibrahim Halil Sahin Subir Goyal Yoanna Pumpalova Mohamad B Sonbol Satya Das Sigurdis Haraldsdottir Daniel Ahn Kristen K Ciombor Zhengjia Chen Amber Draper Jordan Berlin Tanios Bekaii-Saab Gregory B Lesinski Bassel F El-Rayes Christina Wu Source Type: research

Real-World Characteristics, Treatment Patterns, Healthcare Resource Use and Costs of Patients with Diffuse Large B-Cell Lymphoma in the United States
CONCLUSION: This study showed that a large portion of patients require additional therapy after 1L treatment to manage DLBCL, and highlighted the substantial economic burden of DLBCL patients, particularly within the first year following diagnosis.PMID:33616256 | DOI:10.1002/onco.13721 (Source: The Oncologist)
Source: The Oncologist - February 22, 2021 Category: Cancer & Oncology Authors: Xiaoqin Yang Fran çois Laliberté Guillaume Germain Monika Raut Mei Sheng Duh Shuvayu S Sen Dominique Lejeune Kaushal Desai Philippe Armand Source Type: research

Real-World Characteristics, Treatment Patterns, Healthcare Resource Use and Costs of Patients with Diffuse Large B-Cell Lymphoma in the United States
CONCLUSION: This study showed that a large portion of patients require additional therapy after 1L treatment to manage DLBCL, and highlighted the substantial economic burden of DLBCL patients, particularly within the first year following diagnosis.PMID:33616256 | DOI:10.1002/onco.13721 (Source: The Oncologist)
Source: The Oncologist - February 22, 2021 Category: Cancer & Oncology Authors: Xiaoqin Yang Fran çois Laliberté Guillaume Germain Monika Raut Mei Sheng Duh Shuvayu S Sen Dominique Lejeune Kaushal Desai Philippe Armand Source Type: research

Real-World Characteristics, Treatment Patterns, Healthcare Resource Use and Costs of Patients with Diffuse Large B-Cell Lymphoma in the United States
CONCLUSION: This study showed that a large portion of patients require additional therapy after 1L treatment to manage DLBCL, and highlighted the substantial economic burden of DLBCL patients, particularly within the first year following diagnosis.PMID:33616256 | DOI:10.1002/onco.13721 (Source: The Oncologist)
Source: The Oncologist - February 22, 2021 Category: Cancer & Oncology Authors: Xiaoqin Yang Fran çois Laliberté Guillaume Germain Monika Raut Mei Sheng Duh Shuvayu S Sen Dominique Lejeune Kaushal Desai Philippe Armand Source Type: research

Anlotinib, Vincristine and Irinotecan (AVI) for Advanced Ewing Sarcoma after Failure of Standard Multimodal Therapy: A Two-cohort, Phase Ib/II Trial
Oncologist. 2021 Feb 20. doi: 10.1002/onco.13726. Online ahead of print.ABSTRACTBACKGROUND: Both protracted irinotecan and anti-angiogenesis therapy have shown promising efficacy against Ewing sarcoma (EWS). We conducted a phase Ib/II trial to first define the proper dose of irinotecan in combination with vincristine and anlotinib in refractory or recurrent EWS patients (phase Ib) and subsequently evaluate their efficacy (phase II).METHODS: Patients diagnosed with recurrent or refractory EWS were enrolled and further categorized into cohort A (≥ 16 years) or cohort B (
Source: The Oncologist - February 21, 2021 Category: Cancer & Oncology Authors: Jie Xu Lu Xie Xin Sun Kuisheng Liu Xiaodong Tang Taiqiang Yan Rongli Yang Wei Guo Jin Gu Source Type: research

Administration Method of Adjuvant Tegafur-Uracil and Leucovorin Calcium in Patients with Resected Colorectal Cancer: A Phase III Study
Oncologist. 2021 Feb 18. doi: 10.1002/onco.13724. Online ahead of print.NO ABSTRACTPMID:33604941 | DOI:10.1002/onco.13724 (Source: The Oncologist)
Source: The Oncologist - February 19, 2021 Category: Cancer & Oncology Authors: Taishi Hata Kiyotaka Hagihara Anna Tsutsui Hiroki Akamatsu Masayuki Ohue Tatsushi Shingai Mitsuyoshi Tei Masakazu Ikenaga Ho Min Kim Hideki Osawa Hiroyoshi Takemoto Ken Konishi Mamoru Uemura Chu Matsuda Tsunekazu Mizushima Kohei Murata Yuko Ohno Yuichiro Source Type: research

Pre-Emptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial
CONCLUSION: Pre-emptive clobetasol might lessen regorafenib-induced hand-foot reactions compared with reactive therapy. Further confirmatory studies are needed in a larger patient cohort.IMPLICATIONS FOR PRACTICE: Regorafenib causes hand-foot skin reactions. Pre-emotive clobetasol, a high-potency topical corticosteroid, appears to lessen the severity of this adverse event. Although further study is needed, the favorable adverse event profile of this intervention might prompt clinicians to discuss this option with their patients.PMID:33604969 | DOI:10.1002/onco.13730 (Source: The Oncologist)
Source: The Oncologist - February 19, 2021 Category: Cancer & Oncology Authors: Aminah Jatoi Fang-Shu Ou Daniel H Ahn Tyler J Zemla Jennifer G Le-Rademacher Patrick Boland Kristen K Ciombor Nisha L Jacobs Boris Pasche James M Cleary Jeannine S McCune Katrina S Pedersen Afsaneh Barzi E Gabriela Chiorean Erica N Heying Heinz-Josef Lenz Source Type: research

Administration Method of Adjuvant Tegafur-Uracil and Leucovorin Calcium in Patients with Resected Colorectal Cancer: A Phase III Study.
PMID: 33604941 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - February 18, 2021 Category: Cancer & Oncology Authors: Hata T, Hagihara K, Tsutsui A, Akamatsu H, Ohue M, Shingai T, Tei M, Ikenaga M, Kim HM, Osawa H, Takemoto H, Konishi K, Uemura M, Matsuda C, Mizushima T, Murata K, Ohno Y, Doki Y, Eguchi H Tags: Oncologist Source Type: research

Pre-Emptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.
CONCLUSION: Pre-emptive clobetasol might lessen regorafenib-induced hand-foot reactions compared with reactive therapy. Further confirmatory studies are needed in a larger patient cohort. IMPLICATIONS FOR PRACTICE: Regorafenib causes hand-foot skin reactions. Pre-emotive clobetasol, a high-potency topical corticosteroid, appears to lessen the severity of this adverse event. Although further study is needed, the favorable adverse event profile of this intervention might prompt clinicians to discuss this option with their patients. PMID: 33604969 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - February 18, 2021 Category: Cancer & Oncology Authors: Jatoi A, Ou FS, Ahn DH, Zemla TJ, Le-Rademacher JG, Boland P, Ciombor KK, Jacobs NL, Pasche B, Cleary JM, McCune JS, Pedersen KS, Barzi A, Chiorean EG, Heying EN, Lenz HJ, Sloan JA, Grothey A, Lacouture ME, Bekaii-Saab T Tags: Oncologist Source Type: research

Metastatic myxofibrosarcoma with durable response to temozolomide followed by atezoluzimab: A case report.
Abstract Myxofibrosarcoma (MFS) is a well-recognized histotype of soft tissue sarcomas that generally presents with localized disease. Herein, we describe the case of a patient with metastatic MFS who experienced durable response to 6th line therapy with temozolomide. Upon further progression, his tumor was notable for a high tumor mutational burden, and he was subsequently treated with 7th line immunotherapy, atezolizumab, achieving a second durable response. This case highlights the role of immunotherapy following administration of alkylating agents. Review of the literature indicates that recurrent tumors treat...
Source: The Oncologist - February 17, 2021 Category: Cancer & Oncology Authors: Lambden JP, Kelsten MF, Schulte BC, Abbinanti S, Hayes JP, Villaflor V, Agulnik M Tags: Oncologist Source Type: research

A review of immunotherapy for stage 3 and metastatic NSCLC & the rationale for the ECOG-ACRIN EA5181 study.
A review of immunotherapy for stage 3 and metastatic NSCLC & the rationale for the ECOG-ACRIN EA5181 study. Oncologist. 2021 Feb 17;: Authors: Varlotto JM, Sun Z, Ky B, Upshaw J, Katz SI, Fitzgerald TJ, Wakelee H, Diehn M, Mankoff DA, Lovly C, Belani C, Oettel K, Masters G, Ramalingam S, Pennell NA Abstract ECOG-ACRIN EA5181 is a phase III prospective, randomized trial that randomizes patients undergoing chemo/radiation for locally advanced non-small cell lung cancer (LA- NSCLC) to concomitant durvalumab or no additional therapy with both arms receiving one year of consolidative durvalumab. Radiat...
Source: The Oncologist - February 17, 2021 Category: Cancer & Oncology Authors: Varlotto JM, Sun Z, Ky B, Upshaw J, Katz SI, Fitzgerald TJ, Wakelee H, Diehn M, Mankoff DA, Lovly C, Belani C, Oettel K, Masters G, Ramalingam S, Pennell NA Tags: Oncologist Source Type: research

Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma.
CONCLUSION: No difference in overall response rate was observed, leading to early discontinuation of this trial due to low conditional power to detect statistical difference at the planned end of accrual. IMPLICATIONS FOR PRACTICE: Chordoma is a rare neoplasm lacking effective systemic therapies for advanced, unresectable disease. Lack of clinically actionable somatic mutations in chordoma makes development of targeted therapy quite challenging. While the combination of yeast-brachyury vaccine (GI-6301) and standard radiation therapy did not demonstrate synergistic antitumor effects, brachyury still remains a good tar...
Source: The Oncologist - February 17, 2021 Category: Cancer & Oncology Authors: DeMaria PJ, Bilusic M, Park DM, Heery CR, Donahue RN, Madan RA, Bagheri MH, Strauss J, Shen V, Marte JL, Steinberg SM, Schlom J, Gilbert MR, Gulley JL Tags: Oncologist Source Type: research

Optimizing Regorafenib Dosing and Patient Management in Colorectal Cancer in Latin America: Perspectives from Argentina.
PMID: 33594805 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - February 17, 2021 Category: Cancer & Oncology Authors: Dioca M, O'Connor JM Tags: Oncologist Source Type: research

Measuring Ovarian Escape in Premenopausal Estrogen Receptor Positive Breast Cancer Patients on Ovarian Suppression Therapy.
CONCLUSION: Among the premenopausal women who did not attain complete ovarian suppression, young age was a significant risk factor for likelihood of OE. Although the clinical relevance of this finding is not yet known, it should prompt further studies to determine whether inadequate OS is associated with higher recurrence risk for ER+ breast cancer patients. IMPLICATIONS FOR PRACTICE: Because up to a quarter of premenopausal women do not attain adequate ovarian suppression within the first three months of GnRH agonist therapy, bloodwork should be checked to ascertain hormone levels prior to starting aromatase inhibito...
Source: The Oncologist - February 16, 2021 Category: Cancer & Oncology Authors: Burns E, Koca E, Xu J, McLean E, Lee R, Patel T, Chang J, Niravath P Tags: Oncologist Source Type: research

Overcoming Disparities in Cancer: A Need for Meaningful Reform for Hispanic and Latino Cancer Survivors.
Abstract Hispanic and Latino (HL) cancer survivors are at a critical disadvantage compared to non-Hispanic White (NHWs) patients regarding sociodemographic adversities and access to equitable treatment options. By 2030, there will be about four million HL cancer survivors in the US, representing nearly 20% of survivors in this country. Hispanics and Latinos are subjected to significant challenges in accessing and receiving equitable care relative to NHWs. Hispanics and Latinos also experience lower rates of health insurance and financial resources, limiting healthcare options. These disparities often originate fro...
Source: The Oncologist - February 16, 2021 Category: Cancer & Oncology Authors: Kronenfeld JP, Graves K, Penedo FJ, Yanez B Tags: Oncologist Source Type: research

Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors.
CONCLUSION: EPx4 is highly effective and well-tolerated in patients with good-risk GCT, and remains a standard of care. IMPLICATIONS FOR PRACTICE: EPx4 is a standard-of-care regimen for all patients with good-risk GCT with a favorable response rate and disease-specific survival of 98%. Full-dose administration of etoposide and cisplatin and complete resection of residual disease lead to optimal outcomes. EPx4 should be the recommended regimen in active smokers, patients with reduced or borderline kidney function, and patients over age 50, which are patient groups at increased risk for bleomycin pulmonary toxicity. Due...
Source: The Oncologist - February 14, 2021 Category: Cancer & Oncology Authors: Funt SA, McHugh DJ, Tsai S, Knezevic A, O'Donnell D, Patil S, Silber D, Bromberg M, Maryann Carousso NP, Reuter VE, Carver BS, Sheinfeld J, Motzer RJ, Bajorin DF, Bosl GJ, Feldman DR Tags: Oncologist Source Type: research

The First 2  Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions.
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. Oncologist. 2021 Feb 14;: Authors: Bennett CL, Nagai S, Bennett AC, Hoque S, Nabhan C, Schoen MW, Hrushesky WJ, Luminari S, Ray P, Yarnold PR, Witherspoon B, Riente J, Bobolts L, Brusk J, Tombleson R, Knopf K, Fishman M, Yang YT, Carson KR, Djulbegovic B, Restaino J, Armitage JO, Sartor OA Abstract Biosimilars are biologic drug products that are highly similar to reference products in analytic features, pharmacokinetics and pharmacodynamics, im...
Source: The Oncologist - February 14, 2021 Category: Cancer & Oncology Authors: Bennett CL, Nagai S, Bennett AC, Hoque S, Nabhan C, Schoen MW, Hrushesky WJ, Luminari S, Ray P, Yarnold PR, Witherspoon B, Riente J, Bobolts L, Brusk J, Tombleson R, Knopf K, Fishman M, Yang YT, Carson KR, Djulbegovic B, Restaino J, Armitage JO, Sartor OA Tags: Oncologist Source Type: research

Cervical cancer in Sub-Saharan Africa: a multinational population-based cohort study on patterns and guideline adherence of care.
CONCLUSION: We found only one in six cervical cancer patients in SSA received CDT with curative potential. At least one-fifth and possibly up to two thirds of women never accessed CDT, despite curable disease, resulting in impaired OS. Investments into more radiotherapy, chemotherapy, and surgical training could change the fatal outcomes of many patients. PMID: 33565668 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - February 10, 2021 Category: Cancer & Oncology Authors: Griesel M, Seraphin TP, Mezger NC, Hämmerl L, Feuchtner J, Joko-Fru WY, Sengayi-Muchengeti M, Liu B, Vuma S, Korir A, Chesumbai GC, Nambooze S, Lorenzoni CF, Akele-Akpo MT, Ayemou A, Traoré CB, Wondemagegnehu T, Wienke A, Thomssen C, Parkin DM, Jemal A, Tags: Oncologist Source Type: research

Effects of ado-trastuzumab emtansine and fam-trastuzumab deruxtecan on metastatic breast cancer harboring HER2 amplification and the L755S mutation.
In this study, we described a patient with de novo metastatic breast cancer who exhibited both HER2 amplification and the L755S mutation in the untreated primary breast tumor obtained at the initial diagnosis, and the lesion responded to T-DM1 and T-DXd after exhibiting clinical resistance to other HER2-targeted drugs. Our current case findings suggested that anti-HER2 ADCs should be prioritized over conventional trastuzumab- or lapatinib-based therapies for patients with HER2-amplified and co-mutated tumors. KEY POINTS: Although HER2 mutations were implicated in resistance to anti-HER2 monoclonal antibodies or HER2 TKIs i...
Source: The Oncologist - February 9, 2021 Category: Cancer & Oncology Authors: Mukohara T, Hosono A, Mimaki S, Nakayama A, Kusuhara S, Funasaka C, Nakao T, Fukasawa Y, Kondoh C, Harano K, Naito Y, Matsubara N, Tsuchihara K, Kuwata T Tags: Oncologist Source Type: research

Regarding "Hepatitis B surface antigen positivity is an independent unfavorable prognostic factor in diffuse large B-cell lymphoma in the rituximab era".
Regarding "Hepatitis B surface antigen positivity is an independent unfavorable prognostic factor in diffuse large B-cell lymphoma in the rituximab era". Oncologist. 2021 Feb 08;: Authors: Picardi M, Giordano C, Della Pepa R, Pugliese N, Leone A, Delle Cave G, Iula R, Gentile G, Pane F PMID: 33559286 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - February 8, 2021 Category: Cancer & Oncology Authors: Picardi M, Giordano C, Della Pepa R, Pugliese N, Leone A, Delle Cave G, Iula R, Gentile G, Pane F Tags: Oncologist Source Type: research

The effect of concomitant proton pump inhibitor and cabozantinib on the outcomes of patients with metastatic renal cell carcinoma.
CONCLUSION: In line with the pharmacologic data, the concomitant use of PPI does not significantly impact the efficacy or safety of cabozantinib in patients with mRCC. IMPLICATIONS FOR CLINICAL PRACTICE: Proton Pump Inhibitors (PPI) are some of the most prescribed drugs worldwide and they can interact with other oral administered drugs such as Cabozantinib, potentially reducing their efficacy. Cabozantinib is a current therapeutic standard in mRCC, frequently administered with PPI. At the present time there is no evidence regarding the effect of PPIs on Cabozantinib's efficacy and safety in mRCC patients. We hereby de...
Source: The Oncologist - February 8, 2021 Category: Cancer & Oncology Authors: Rassy E, Cerbone L, Auclin E, Benchimoll-Zouari A, Flippot R, Alves Costa Silva C, Colomba E, Geraud A, Guida A, Mir O, Combarel D, Paci A, Escudier B, Albiges L Tags: Oncologist Source Type: research

Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma.
CONCLUSION: Avelumab in combination with radiotherapy for patients with RRMM and EMD was associated with very modest systemic clinical benefit; however, patients did benefit as usual from local radiotherapy. Furthermore, the combination was very well tolerated compared with historical RRMM treatment regimens. PMID: 33554406 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - February 8, 2021 Category: Cancer & Oncology Authors: Kazandjian D, Dew A, Hill E, Ramirez EG, Morrison C, Mena E, Lindenberg L, Yuan C, Maric I, Wang HW, Calvo K, Dulau-Florea A, Roswarski J, Emanuel M, Braylan R, Turkbey B, Choyke P, Camphausen K, Stetler-Stevenson M, Steinberg SM, Figg WD, Jones J Tags: Oncologist Source Type: research

Health-Related Quality of Life in Patients with Breast Cancer in Latin America and the Caribbean: A Systematic Review and Meta-Analysis.
CONCLUSION: This study provides a synthesis of breast cancer HRQoL reported in LAC and exposes existing evidence gaps. Patients with BC in active treatment or with metastatic disease had worse HRQoL compared with survivors during the follow-up period. IMPLICATIONS FOR PRACTICE: This systematic review study provides an exhaustive synthesis of breast cancer health-related quality of life in women in the Latin American and Caribbean region. Patients with breast cancer in active treatment or with metastatic disease had worse health-related quality of life compared with survivors during the different follow-up periods. Thi...
Source: The Oncologist - February 8, 2021 Category: Cancer & Oncology Authors: Gonzalez L, Bardach A, Palacios A, Peckaitis C, Ciapponi A, Pichón-Riviere A, Augustovski F Tags: Oncologist Source Type: research

Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data.
CONCLUSION: Low adherence to antiemetic guidelines was revealed in clinical practice in five European countries, with 15% of all HEC-/carboplatin-based treatments receiving guideline-recommended NK1 RA-5-HT3 RA-dexamethasone prophylaxis, and 12% of them receiving no antiemetics. New strategies for improving guideline adherence are urgently needed. IMPLICATIONS FOR PRACTICE: Despite recent advances in antiemetic therapy, a substantial proportion of patients experience nausea and vomiting associated with chemotherapy in daily clinical practice. Antiemetic guidelines aim at prevention of chemotherapy-induced nausea and v...
Source: The Oncologist - February 8, 2021 Category: Cancer & Oncology Authors: Aapro M, Scotté F, Escobar Y, Celio L, Berman R, Franceschetti A, Bell D, Jordan K Tags: Oncologist Source Type: research

Circulating tumor DNA (ctDNA) based testing and actionable findings in patients with advanced and metastatic pancreatic adenocarcinoma.
CONCLUSION: Our study is the largest cohort to date that demonstrates the feasibility of ctDNA testing in PDAC. We provide a benchmark landscape upon which the field can continue to grow. Future applications may include use of ctDNA to guide treatment and serial monitoring of ctDNA during disease course to identify novel therapeutic targets for improved prognosis. IMPLICATIONS FOR PRACTICE: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis often due to late presentation of disease. Biopsy tissue sampling is invasive and samples are often inadequate, requiring repeated invasive procedures and delays in treat...
Source: The Oncologist - February 8, 2021 Category: Cancer & Oncology Authors: Botrus G, Kosirorek H, Sonbol MB, Kusne Y, Uson Junior PLS, Borad MJ, Ahn DH, Pashtoon KM, Drusbosky LM, Dada H, Surapaneni PK, Starr J, Ritter A, McMillan J, Wylie N, Mody K, Bekaii-Saab TS Tags: Oncologist Source Type: research

A novel malignant peritoneal mesothelioma with STRN exon 2 and ALK exon 20 : a case report and literature review.
Abstract Recently, several malignant peritoneal mesothelioma (MPMs) that occur in young women without asbestos exposure and with fusion genes such as anaplastic lymphoma kinase (ALK) and Ewing sarcoma breakpoint region 1 (EWSR1) have been reported. In the present case, we encountered MPM with STRN-ALK fusion in a 17-year-old female. The case did not respond to chemotherapy and is currently in a clinical trial of alectinib. This is the fourth reported case of MPM with STRN-ALK fusion. Of the 45 cancer cases with STRN-ALK fusion in which the fusion partners were examined, all cases except for the current case showed...
Source: The Oncologist - February 8, 2021 Category: Cancer & Oncology Authors: Miyagawa C, Takaya H, Sakai K, Nishio K, Konishi M, Minamiguchi S, Shimada T, Matsumura N Tags: Oncologist Source Type: research

College of American Pathologists Tumor Regression Grading System for Long-term Outcome in Patients with Locally Advanced Rectal Cancer.
Abstract BACKGROUND: NCCN's Rectal Cancer Guideline Panel recommends American Joint Committee of Cancer and College of American Pathologists tumor regression grading (AJCC/CAP TRG) system to evaluate pathologic response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer (LARC). Yet, the clinical significance of AJCC/CAP TRG system has not been fully defined. METHODS: This was a multicenter, retrospectively recruited, and prospectively maintained cohort study. Patients with LARC from one institution formed the discovery set, and cases from external independent institutions formed validation se...
Source: The Oncologist - February 4, 2021 Category: Cancer & Oncology Authors: Chen HY, Feng LL, Li M, Ju HQ, Ding Y, Lan M, Song SM, Han WD, Yu L, Wei MB, Pang XL, He F, Liu S, Zheng J, Ma Y, Lin CY, Lan P, Huang MJ, Zou YF, Yang ZL, Wang T, Lang JY, Orangio GR, Poylin V, Ajani JA, Wang WH, Wan XB Tags: Oncologist Source Type: research

FOLFOXIRI + bevacizumab versus FOLFOX + panitumumab for metastatic left sided RAS/BRAF wild type colorectal cancer: Which "side" are you on?
FOLFOXIRI + bevacizumab versus FOLFOX + panitumumab for metastatic left sided RAS/BRAF wild type colorectal cancer: Which "side" are you on? Oncologist. 2021 Feb 04;: Authors: Yu IS, Loree JM Abstract This commentary focuses on the results of Pietrantonio et al.'s recent manuscript evaluating the clinical conundrum of triplet versus doublet chemotherapy in combination with targeted therapy for metastatic left sided RAS/BRAF wild type colorectal cancer. Both FOLFOXIRI + bevacizumab and FOLFOX + panitumumab have shown impressive activity in this population, however the two have not been direct...
Source: The Oncologist - February 4, 2021 Category: Cancer & Oncology Authors: Yu IS, Loree JM Tags: Oncologist Source Type: research

Feasibility and predictive performance of a triage system for cancer patients during the COVID-19 pandemic.
Abstract BACKGROUND: Triage procedures have been implemented to limit hospital access and minimize infection risk among cancer patients during the COVID-19 outbreak. In the absence of prospective evidence, we aim to evaluate the predictive performance of a triage system in the oncological setting. PATIENTS AND METHODS: This retrospective cohort study analyzes hospital admissions to the Oncology and Hematology Department of Udine, Italy, during the COVID-19 pandemic (March 30th to April 30th , 2020). A total of 3923 triage procedures were performed, and data of 1363 individual patients were reviewed. RESU...
Source: The Oncologist - February 4, 2021 Category: Cancer & Oncology Authors: Fasola G, Pelizzari G, Zara D, Targato G, Petruzzellis G, Minisini AM, Bin A, Donato R, Mansutti M, Comuzzi C, Candoni A, Sperotto A, Fanin R Tags: Oncologist Source Type: research

Global Precision Oncology: A Call to Action on Expanding Access to Targeted Cancer Therapies.
PMID: 33539588 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - February 4, 2021 Category: Cancer & Oncology Authors: Bharadwaj M, Vallurupalli M, Huang FW Tags: Oncologist Source Type: research

In Regard toA phase Ib study of NUC-1031 in combination with cisplatin for the first-line treatment of patients with advanced biliary tract cancer (ABC-08).
PMID: 33539601 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - February 4, 2021 Category: Cancer & Oncology Authors: Ricci AD, Rizzo A, Brandi G Tags: Oncologist Source Type: research

In Reply.
PMID: 33539624 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - February 4, 2021 Category: Cancer & Oncology Authors: McNamara MG, Valle JW Tags: Oncologist Source Type: research

KRAS-mutated, ER-positive low-grade serous ovarian cancer: Unraveling an exceptional response mystery.
This report demonstrates remarkable response for KRAS-mutated, ER-positive low-grade serous ovarian cancer patient treated with trametinib (MEK inhibitor) and letrozole (aromatase inhibitor), despite prior progression on similar agents including tamoxifen (estrogen modulator). In vitro investigation revealed that tamoxifen can have agonistic in addition to antagonistic effects, which could be the reason patient was not responding to combination of trametinib and tamoxifen. Our current observations suggest that drugs with different mechanisms of action targeting the same receptor may have markedly different anti-cancer acti...
Source: The Oncologist - February 2, 2021 Category: Cancer & Oncology Authors: Kato S, McFall T, Takahashi K, Bamel K, Ikeda S, Eskander RN, Plaxe S, Parker B, Stites E, Kurzrock R Tags: Oncologist Source Type: research

Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics.
Abstract The cyclin pathway may confer resistance to standard treatments but also offer novel therapeutic opportunities in prostate cancer. In this article, we analyzed prostate cancer samples (majority metastatic) using comprehensive genomic profiling performed by next-generation sequencing (315 genes,>500× coverage) for alterations in activating and sensitizing cyclin genes (CDK4 amplification, CDK6 amplification, CCND1, CCND2, CCND3, CDKN2B [loss], CDKN2A [loss], SMARCB1), androgen receptor (AR) gene, and coalterations in genes leading to cyclin inhibitor therapeutic resistance (RB1 and CCNE1). Overall...
Source: The Oncologist - February 1, 2021 Category: Cancer & Oncology Authors: Jardim D, Millis SZ, Ross JS, Woo MS, Ali SM, Kurzrock R Tags: Oncologist Source Type: research

Implementing Historical Controls in Oncology Trials.
Abstract XXXX IMPLICATIONS FOR PRACTICE: Leveraging the information brought by historical controls could shorten development time and reduce the number of patients enrolled. Careful selection of the past studies, a prespecified statistical analysis accounting for the heterogeneity between studies, and early engagement with regulators will be key to success. Although both the European Medicines Agency and the U.S. Food and Drug Administration have already approved medicines based on nonrandomized experiments, the evidentiary package can, however, be perceived as less comprehensive than randomized ones. Use of histo...
Source: The Oncologist - February 1, 2021 Category: Cancer & Oncology Authors: Collignon O, Schritz A, Spezia R, Senn SJ Tags: Oncologist Source Type: research

Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response.
This study aimed to prospectively evaluated neuropathy development and deficits from weekly paclitaxel treatment and evaluate the impact of dose reduction on posttreatment neuropathy outcomes. PATIENTS AND METHODS: Patients with breast cancer receiving paclitaxel (80 mg/m2 ) weekly for 12 weeks were prospectively recruited (precycle 1 paclitaxel). Comprehensive patient-reported (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity; FACT-GOG-Ntx) clinical (Total Neuropathy Score clinical version; TNSc) and neurophysiological measures were used to assess neuropathy development and reco...
Source: The Oncologist - February 1, 2021 Category: Cancer & Oncology Authors: Timmins HC, Li T, Trinh T, Kiernan MC, Harrison M, Boyle F, Friedlander M, Goldstein D, Park SB Tags: Oncologist Source Type: research

Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies.
This study was conducted through a single-center retrospective chart review of 125 patients with primary and metastatic brain tumors on anticoagulation. Our primary outcomes were major bleeding and intracranial hemorrhage (ICH) with secondary outcomes of minor bleeding and recurrent thrombosis. The rate of major bleeding was 26% in the LMWH group versus 9.6% in the DOAC group (p = .03). The rate of ICH was 15% in the LMWH group versus 5.8% in the DOAC group (p = .12). The severity of ICH in both groups was low with median Common Terminology Criteria for Adverse Events version 5 scores of 2 in the LMWH group and 3 in the DO...
Source: The Oncologist - February 1, 2021 Category: Cancer & Oncology Authors: Swartz AW, Drappatz J Tags: Oncologist Source Type: research

Caregiver-oncologist prognostic concordance, caregiver mastery, and caregiver psychological health and quality of life.
Abstract BACKGROUND: Caregivers of adults with cancer often report a different understanding of the patient's prognosis than the oncologist. We examine the associations of caregiver-oncologist prognostic concordance with caregiver depressive symptoms, distress, and quality of life (QoL). We also explore whether these relationships differed by caregiver environment mastery, an individual's sense of control and effectiveness in managing life situations. METHODS: We used data from a national geriatric assessment cluster-randomized trial (URCC 13070) that recruited patients aged ≥70 with incurable cancer consi...
Source: The Oncologist - February 1, 2021 Category: Cancer & Oncology Authors: Loh KP, Mohamed MR, Kadambi S, Culakova E, Xu H, Magnuson A, Flannery M, Duberstein PR, Epstein RM, McHugh C, Nipp RD, Trevino KM, Sanapala C, Hall BA, Canin B, Gayle AA, Conlin A, Bearden J, Mohile SG Tags: Oncologist Source Type: research

Radiotherapy-PCV versus radiotherapy-temozolomide for IDH-mutant anaplastic astrocytoma: a retrospective multicentre analysis of the French POLA cohort.
Abstract BACKGROUND: IDH-mutant anaplastic astrocytomas (AA) are chemosensitive tumours for which the best choice of adjuvant chemotherapy between procarbazine, CCNU and vincristine (PCV) or temozolomide (TMZ) after radiotherapy (RT) remains unclear. METHODS: In a large cohort of patients with histologically proven WHO 2016 AA with IDH1/2 mutations included in the French national POLA cohort (n=355), the primary objective was to compare progression-free survival (PFS) between the two treatment regimens (n=311). Secondary endpoints were overall survival (OS), progression type, pseudoprogression rate, and toxic...
Source: The Oncologist - February 1, 2021 Category: Cancer & Oncology Authors: Esteyrie V, Dehais C, Martin E, Carpentier C, Uro-Coste E, Figarella-Branger D, Bronniman C, Pouessel D, Ciron DL, Ducray F, Moyal EC, POLA Network Tags: Oncologist Source Type: research

Cancer of unknown primary presenting as bone-predominant or lymph node-only disease: a clinicopathologic portrait.
Abstract BACKGROUND: Cancer of unknown primary (CUP) presenting as bone-predominant (BCUP) or lymph node-only disease (LNCUP) represents two clinically distinct subsets of non-visceral CUP. These present a diagnostic challenge with a large differential of putative primary cancers and defy the "one-treatment-fits-all" approach. METHODS: We identified patients with BCUP (N=29) and LNCUP (N=63) using a prospectively collected CUP database and tumor registry of patients seen at MD Anderson Cancer Center between 2001 to 2017. Clinicopathological characteristics, treatments, and outcomes were abstracted. ...
Source: The Oncologist - February 1, 2021 Category: Cancer & Oncology Authors: Huey RW, Smaglo BG, Estrella JS, Matamoros A, Overman MJ, Varadhachary GR, Raghav KPS Tags: Oncologist Source Type: research

Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma.
CONCLUSION: Identification of varied molecular features by targeted next-generation sequencing provides more insight into patient stratification and offers more possibilities for both targeted therapies and immunotherapies of Chinese patients with GC. IMPLICATIONS FOR PRACTICE: The submitted study investigated the genomic alteration profile of 529 Chinese patients with gastric adenocarcinoma by deep targeting sequencing, which might be the largest Chinese cohort on the genomic research of gastric adenocarcinoma up to now. PMID: 33511732 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - January 29, 2021 Category: Cancer & Oncology Authors: Yu P, Wang Y, Yu Y, Wang A, Huang L, Zhang Y, Liu W, Wu H, Yao M, Du YA, Cheng X Tags: Oncologist Source Type: research

Activity of Sorafenib plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer.
CONCLUSION: SorCape in this heavily pre-treated population yielded a reasonable PFS with manageable, but notable toxicity. The combination should be investigated further. PMID: 33512054 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - January 29, 2021 Category: Cancer & Oncology Authors: George TJ, Ivey AM, Ali A, Lee JH, Wang Y, Daily KC, Ramnaraign BH, Tan SA, Terracina KP, Read TE, Dang LH, Iqbal A Tags: Oncologist Source Type: research

Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer?
CONCLUSION: SC may not be efficacious in preventing alopecia in Black women. Differences in hair thickness, hair volume, and limitations of cooling cap design are possible contributing factors. RESULTS: 15 patients enrolled in the intervention before the study was closed early due to lack of efficacy. Median MDS and CADS increased after SC suggesting increased hair loss (p 50% hair loss). PMID: 33512741 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - January 29, 2021 Category: Cancer & Oncology Authors: Dilawari A, Gallagher C, Alintah P, Chitalia A, Tiwari S, Paxman R, Adams-Campbell L, Dash C Tags: Oncologist Source Type: research

Selinexor, a First in Class, Nuclear Export Inhibitor for the Treatment of Advanced Malignant Peripheral Nerve Sheath Tumor.
Abstract Malignant peripheral nerve sheath tumor (MPNST) is a highly malignant neoplasm arising from peripheral nerve or its attendant sheath and is derived from Schwann or pluripotent cells of neural crest origin. Patients with recurrent, unresectable, or advanced stage disease have limited treatment options, and current therapies are associated with little benefit. In this article, we report nine cases of MPNST treated with selinexor, an orally bioavailable, selective inhibitor of nuclear export, accompanied by tumor stabilization or regression. PMID: 33512749 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - January 29, 2021 Category: Cancer & Oncology Authors: Al-Ezzi E, Gounder M, Watson G, Mazzocca A, D'Angelo SP, Bravetti J, Wang H, Razak AA, Vincenzi B Tags: Oncologist Source Type: research

Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors.
CONCLUSIONS: Among NET G3 patients, CAPTEM was the most commonly used treatment with clinically meaningful efficacy and disease control. FOLFOX or PRRT are other potentially active treatment options. EP has some activity in NET G3 but responses appear to be short-lived. Prospective studies evaluating different treatments effects in NET G3 patients are needed to determine an optimal treatment strategy. IMPLICATIONS FOR PRACTICE: High-grade well differentiated neuroendocrine tumors (NET G3) are considered different entity from low-grade NET and neuroendocrine carcinoma in terms of prognosis and management. The oral comb...
Source: The Oncologist - January 26, 2021 Category: Cancer & Oncology Authors: Liu AJ, Ueberroth BE, McGarrah PW, Buckner Petty SA, Kendi AT, Starr J, Hobday TJ, Halfdanarson TR, Sonbol MB Tags: Oncologist Source Type: research

Impact of obesity on quality of life, psychological distress, and coping on patients with colon cancer.
The objective was to assess differences in clinical-pathological and psychosocial variables between obese and non-obese individuals with colon cancer. PATIENTS AND METHODS: Prospective, multicentric, observational study conducted from 2015-2018. The sample comprised patients with stage II-III, resected colon cancer about to initiate adjuvant chemotherapy with fluoropyrimidine in monotherapy or associated with oxaliplatin and grouped into non-obese (BMI
Source: The Oncologist - January 25, 2021 Category: Cancer & Oncology Authors: Gomez D, Jimenez-Fonseca P, Manzano Fernández A, Cruz Castellanos P, Valero Arbizu M, Martínez Cabañes R, Lorente Estellés D, Ferreira E, Del Rio J, García García T, Carmona-Bayonas A, Calderon C Tags: Oncologist Source Type: research

Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors.
CONCLUSION: Overall, pembrolizumab was safe and had limited antitumor activity in these patients. In the advanced, metastatic setting, tumor profiling to understand the mechanisms of resistance to immunotherapy and innovative clinical trials to identify efficacious combination regimens rather than off-label use of pembrolizumab are warranted. DISCUSSION: Germ cell tumors are associated with a diverse histopathology and clinical prognosis. Approximately 20%-30% of patients with metastatic germ cell tumors have disease resistant to standard chemotherapy [1], and 15%-20% of these tumors are incurable with the available t...
Source: The Oncologist - January 24, 2021 Category: Cancer & Oncology Authors: Tsimberidou AM, Vo HH, Subbiah V, Janku F, Piha-Paul S, Yilmaz B, Gong J, Faraz Naqvi M, Tu SM, Campbell M, Meric-Bernstam F, Naing A Tags: Oncologist Source Type: research

Long-Term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis With Up to 5  Years of Follow-Up.
Long-Term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis With Up to 5 Years of Follow-Up. Oncologist. 2021 Jan 23;: Authors: Finn RS, Rugo HS, Gelmon KA, Cristofanilli M, Colleoni M, Loi S, Schnell P, Lu DR, Theall KP, Mori A, Gauthier E, Bananis E, Turner NC, Diéras V Abstract BACKGROUND: Previous studies demonstrated the tolerability of palbociclib plus endocrine therapy (ET). This analysis evaluated safety based on more recent cutoff dat...
Source: The Oncologist - January 23, 2021 Category: Cancer & Oncology Authors: Finn RS, Rugo HS, Gelmon KA, Cristofanilli M, Colleoni M, Loi S, Schnell P, Lu DR, Theall KP, Mori A, Gauthier E, Bananis E, Turner NC, Diéras V Tags: Oncologist Source Type: research